Russia has developed the first cancer vaccine, which is expected to be administered to melanoma patients in the coming months. The treatment, which has been developed as an mRNA vaccine, is called “Enteromix”.
Alexander Ginzburg, director of the National Research Center for Epidemiology and Microbiology (N.F. Gamalei), announced the start of the administration of the vaccine, which has been developed based on the personal genetic information of each patient, and specifically concerns cancer patients.
Clinical trials in melanoma patients
A. Ginzburg stated that, according to the plan approved by the Russian Ministry of Health, the vaccine will be administered experimentally to a group of melanoma patients in collaboration with the Moskva Scientific Research Oncology Institute “Gertsen” and the National Medical Research Center of Oncology “Blokhin”.
The process will begin soon, with the aim of early administration of the vaccine to patients. Alexander Ginzburg said that the Gamalei Center is exclusively engaged in the production of the vaccine, which is based on “neoantigens” designed specifically for each patient.
The role of the vaccine is fundamentally different from other pharmaceutical agents, as its application is individual and limited to the specific patient.
Russia is a pioneer in cancer research
The creation of the vaccine comes as a continuation of the efforts of Russian scientists in the field of cancer.
Earlier, the Federal Scientific Clinical Center of Medical Radiology and Oncology of Russia in the city of Dimitrovgrad announced the development of a new therapeutic vaccine for the treatment of serious forms of cancer.
A. Ginzburg emphasized that Russia seeks to offer this vaccine free of charge to Russian citizens, and clinical trials to select the first participants began in December 2024.
Participants must have already exhausted other approved methods of treatment and suffer from solid tumors, that is, cancer that is not related to the blood.
The vaccine was created in collaboration with the Gamalei Center, the Moscow Scientific Research Oncology Institute “P.A. Gertsen” and the National Medical Research Center of Oncology “N.N. Blokhin”. Scientists promise that the vaccine will be available free of charge to Russian citizens.
It is noteworthy that candidate biologist Vyacheslav Kosorukov reported that the treatment is developed individually for each patient and, after surgery, has the potential to act therapeutically to prevent recurrent cancer development.
